TY - JOUR
T1 - Clearance of mycoplasma genitalium and trichomonas vaginalis among adolescents and young adults with pelvic inflammatory disease
T2 - Results from the tech-N study
AU - Trent, Maria
AU - Yusuf, Hasiya E.
AU - Perin, Jamie
AU - Anders, Jennifer
AU - Chung, Shang En
AU - Tabacco-Saeed, Lisa
AU - Rowell, Julia
AU - Huettner, Steven
AU - Rothman, Richard
AU - Butz, Arlene
AU - Gaydos, Charlotte A.
N1 - Publisher Copyright:
Copyright © 2020 American Sexually Transmitted Diseases Association. All rights reserved.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Current pelvic inflammatory disease (PID) treatment effectively treats Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT). However, coverage may be inadequate for Mycoplasma genitalium (MG)/ Trichomonas vaginalis (TV) infections. We compared the longitudinal MG and TVoutcomes with NG/CToutcomes for women enrolled in a longitudinal randomized controlled trial to optimize outcomes after PID. The prevalences of CT and NG were lower at 30- and 90-day follow-up compared with the prevalence at the time of diagnosis.No significant difference was observed for MG (odds ratio, 0.95; 0.86-1.04; P = 0.265) and TV (odds ratio, 0.89; 0.75-1.04; P = 0.146) over time for both treatment groups, showing that persistence and/or reinfection with MG and TVoccurs more frequently than with CTor NG after treatment of PID using current national treatment guidelines.
AB - Current pelvic inflammatory disease (PID) treatment effectively treats Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT). However, coverage may be inadequate for Mycoplasma genitalium (MG)/ Trichomonas vaginalis (TV) infections. We compared the longitudinal MG and TVoutcomes with NG/CToutcomes for women enrolled in a longitudinal randomized controlled trial to optimize outcomes after PID. The prevalences of CT and NG were lower at 30- and 90-day follow-up compared with the prevalence at the time of diagnosis.No significant difference was observed for MG (odds ratio, 0.95; 0.86-1.04; P = 0.265) and TV (odds ratio, 0.89; 0.75-1.04; P = 0.146) over time for both treatment groups, showing that persistence and/or reinfection with MG and TVoccurs more frequently than with CTor NG after treatment of PID using current national treatment guidelines.
UR - http://www.scopus.com/inward/record.url?scp=85092945899&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092945899&partnerID=8YFLogxK
U2 - 10.1097/OLQ.0000000000001221
DO - 10.1097/OLQ.0000000000001221
M3 - Article
C2 - 32569258
AN - SCOPUS:85092945899
SN - 0148-5717
VL - 47
SP - e47-e50
JO - Sexually transmitted diseases
JF - Sexually transmitted diseases
IS - 11
ER -